



- **FACT SHEET No. 8**

## **Alternative Treatment Options for Osteoarthritis: Facts and Evidence on Glucosamines and Chondroitin**

[Peter Jüni](#)

Glucosamines and chondroitin are constituents of joint cartilage. Their oral administration in patients with osteoarthritis is thought to make up for the apparent cartilage loss in affected joints. Therefore, they are commonly used as dietary supplements that are claimed to reduce the symptoms of osteoarthritis and delay its progression. [1]

Glucosamine is an amino sugar that is a building block for the glycosaminoglycans that are part of the structure of cartilage. Glucosamine can be taken as a pill or sometimes as an injection. It can come in combination with other supplements (such as chondroitin) or by itself in the form of glucosamine hydrochloride or sulphate. [2] Chondroitin is a highly hydrophilic, gel-forming polysaccharide macromolecule, which conveys much of the compressive resistance of cartilage. It is mainly available in the form of chondroitin sulfate. [3] Ingested chondroitin and glucosamine are both partially absorbed in the intestine, and it has been suggested that some of the ingested amount reaches the joints.

Until recently, the research evidence has suffered from being small scale and poor in quality; several reviews have highlighted the need for larger and better quality studies [4, 5], and some have recently been published.

In a network meta-analysis that included ten large trials in 3,803 patients available up to June 2010, the overall difference in pain intensity on a 10 cm visual analog scale compared with placebo was  $-0.4$  cm (95 percent confidence interval  $-0.7$  to  $-0.1$  cm) for glucosamine,  $-0.3$  cm ( $-0.7$  to  $0.0$  cm) for



© Copyright 2016 International Association for the Study of Pain. All rights reserved.

**IASP brings together scientists, clinicians, health-care providers, and policymakers to stimulate and support the study of pain and translate that knowledge into improved pain relief worldwide.**


chondroitin, and  $-0.5$  cm ( $-0.9$  to  $0.0$  cm) for the combination.[6] None of these differences reached clinical relevance, as none of them reached the minimal clinically important difference of  $0.9$  cm.

The figure below presents pooled estimates across different time points. The variation across time points was not over and above what would be expected by chance. Industry independent trials showed systematically smaller effects than commercially funded trials.

The differences in changes in minimal width of joint space were all minute, with 95 percent confidence intervals all overlapping zero. The difference was  $-0.2$ mm ( $-0.3$  to  $0.0$  mm) in favor of glucosamine,  $-0.1$  mm ( $-0.3$  to  $0.1$  mm) in favor of chondroitin, and  $0.0$ mm ( $-0.2$  to  $0.2$  mm) for the combination. Results of the network meta-analysis did not indicate that the use of these supplements is unsafe, but given the scarcity of information and wide 95 percent confidence intervals of estimates, evidence is inconclusive.

One large trial has become available since publication of the network meta-analysis. The LEGS trial published in 2015 [7] randomized 605 patients to glucosamine sulfate, chondroitin sulfate, both dietary supplements, or matching placebo capsules. Results were also concordant with the network meta-analysis, with no relevant effect of either of the supplements or their combination on pain or joint space width.

Compared with placebo, glucosamine, chondroitin, and their combination do not reduce joint pain or have an impact on narrowing of joint space. The likely industry-sponsorship of the majority of trials may have led to an overestimation of treatment benefits.[6, 8] Health authorities and health insurers should not cover the costs of these preparations, and new prescriptions to patients who have not received treatment should be discouraged.[6]



Differences in pain intensity measured on visual analog scale (VAS) between experimental interventions and placebo over time. The darker shading between -0.9 and +0.9 cm represents area of clinical equivalence. Negative values indicate benefit of experimental interventions compared with placebo. Pain reductions of -0.9cm or more are deemed clinically relevant, smaller differences are not. Adapted from Wandel et al.[6]

## References

1. Juni, P., S. Reichenbach, and P. Dieppe, Osteoarthritis: rational approach to treating the individual. *Best Pract Res Clin Rheumatol*, 2006. 20(4): p. 721-40.
2. Towheed, T., et al. Glucosamine for osteoarthritis. 2009 28.04.2015]; Available from: [www.cochrane.org/CD002946/MUSKEL\\_glucosamine-for-osteoarthritis](http://www.cochrane.org/CD002946/MUSKEL_glucosamine-for-osteoarthritis).
3. Singh, J.A., et al. Chondroitin for osteoarthritis. 2015; Available from [www.cochrane.org/CD005614/MUSKEL\\_chondroitin-for-osteoarthritis](http://www.cochrane.org/CD005614/MUSKEL_chondroitin-for-osteoarthritis).
4. McAlindon, T.E., et al., Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. *JAMA*, 2000. 283(11): p. 1469-75.
5. Chard, J. and P. Dieppe, Glucosamine for osteoarthritis: magic, hype, or confusion? It's probably safe-but there's no good evidence that it works. *BMJ*, 2001. 322(7300): p. 1439-40.
6. Wandel, S., et al., Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. *BMJ*, 2010. 341: p. c4675.
7. Franssen, M., et al., Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. *Ann Rheum Dis*, 2015. 74(5): p. 851-8.
8. Bekelman, J.E., Y. Li, and C.P. Gross, Scope and impact of financial conflicts of interest in biomedical research: a systematic review. *JAMA*, 2003. 289(4): p. 454-65.

### About the International Association for the Study of Pain®

IASP is the leading professional forum for science, practice, and education in the field of pain. [Membership is open to all professionals](#) involved in research, diagnosis, or treatment of pain. IASP has more than 7,000 members in 133 countries, 90 national chapters, and 20 Special Interest Groups.

Plan to join your colleagues at the [16th World Congress on Pain](#), September 26-30, 2016, in Yokohama, Japan.

**As part of the Global Year Against Pain in the Joints, IASP offers a series of 20 Fact Sheets that cover specific topics related to joint pain. These documents have been translated into multiple languages and are available for free download. Visit [www.iasp-pain.org/globalyear](http://www.iasp-pain.org/globalyear) for more information.**



© Copyright 2016 International Association for the Study of Pain. All rights reserved.

**IASP brings together scientists, clinicians, health-care providers, and policymakers to stimulate and support the study of pain and translate that knowledge into improved pain relief worldwide.**